With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen nutritional period in Oregon, Washington medicine and Idaho together suppliers showed a greater nutritional reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior medicine to the treatment in 1995 and one year later suppliers in 1996. They were immunoassayed for specific IgE antibodies nutritional using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing medicine average baseline IgE levels to one-year. For the seasonal suppliers allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out nutritional and medicine of 16 allergens.8

All suppliers of the nutritional active B12 group medicine reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the suppliers placebo controls reported either no change or a worsening nutritional of symptoms. Wilcoxon-Rank of .002 for the end-points medicine of sneezing, suppliers nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 nutritional on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged medicine the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. suppliers In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite nutritional intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm medicine did not develop in the second suppliers metabisulfite challenge.6